WHWalter H. Hörl

Walter H. Hörl

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Walter H. Hörl has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Fernando Valderrábano

    From the Klinische Abteilung für Nephrologie und Dialyse, Universitätsklinik für Innere Medizin III, Wien, Austria; Department of Renal Medicine, King's College Hospital, London, UK; INSERM U489, Service de Néphrologie, Hôpital Tenon, Paris, France; Klinika Chorob Nerek AM, Gdansk, Poland; Division of Nephrology, University Hospital Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; and Servicio Nefrologıa, Hospital Gregorio Marañon, Madrid, Spain

    2 shared publications
  • Boleslaw Rutkowski

    From the Klinische Abteilung für Nephrologie und Dialyse, Universitätsklinik für Innere Medizin III, Wien, Austria; Department of Renal Medicine, King's College Hospital, London, UK; INSERM U489, Service de Néphrologie, Hôpital Tenon, Paris, France; Klinika Chorob Nerek AM, Gdansk, Poland; Division of Nephrology, University Hospital Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; and Servicio Nefrologıa, Hospital Gregorio Marañon, Madrid, Spain

    1 shared publication
  • Claude Jacobs

    1 shared publication
  • Gerald Cohen

    Division of Nephrology and Dialysis, Department of Medicine III, University of Vienna, Vienna, Austria

    1 shared publication
  • Gere Sunder-Plassmann

    Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria

    1 shared publication
  • Iain C. Macdougall

    From the Klinische Abteilung für Nephrologie und Dialyse, Universitätsklinik für Innere Medizin III, Wien, Austria; Department of Renal Medicine, King's College Hospital, London, UK; INSERM U489, Service de Néphrologie, Hôpital Tenon, Paris, France; Klinika Chorob Nerek AM, Gdansk, Poland; Division of Nephrology, University Hospital Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; and Servicio Nefrologıa, Hospital Gregorio Marañon, Madrid, Spain

    1 shared publication

Latest Publications

  • The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes

    by Walter H. Hörl

    Secondary hyperparathyroidism (SHPT) is a common occurrence in patients with chronic renal failure and is characterized by excessive serum parathyroid hormone (PTH) levels, parathyroid hyperplasia and imbalances in calcium and phosphorus metabolism. PTH acts as a uraemic toxin and it may be responsible for the following long-term consequences: renal osteodystrophy; non-skeletal abnormalities, including severe vascular and heart valve calcification; alterations in cardiovascular structure and function; immune dysfunction; and renal anaemia. The risk of developing SHPT is not the same for all uraemic patients. Black patients appear to have a higher risk of developing SHPT than Caucasian patients, and patients with diabetes have a lower risk than non-diabetic patients. Current treatments include dietary phosphate restriction, oral phosphate binders, vitamin D and its analogues, and, in severe cases, parathyroidectomy. These treatments do not provide optimal treatment for many patients, and compounds that directly inhibit PTH secretion may prove a major step forward in the treatment of SHPT.


  • Open Access

    Effects of Tamm-Horsfall protein on polymorphonuclear leukocyte function

    by Thomas Wimmer, Gerald Cohen, Marcus D. Saemann, Walter H. Hörl

    Background. Tamm–Horsfall protein (THP), a glycoprotein produced exclusively by renal tubular cells, is thought to be involved in several inflammatory disorders such as bacterial interstitial nephritis as well as in defence against uropathogenic microorganisms. The specific effects of THP on inflammatory cells, however, are not yet well known. Therefore, the present study investigates the effects of THP in its soluble form on distinct polymorphonuclear leukocyte (PMNL) functions. Methods. PMNL were isolated from the venous blood of healthy adult donors and incubated at low THP concentrations (70–350 ng/ml), resembling plasma concentrations, and at high THP concentrations (1.75–8.75 µg/ml), resembling urinary concentrations. Results. High (urinary) THP concentrations inhibited PMNL apoptosis and chemotaxis and stimulated PMNL phagocytosis, while low (plasma) THP concentrations increased PMNL chemotaxis. Conclusions. These data indicate that THP influences several PMNL functions, suggesting a crucial immunomodulatory role for this glycoprotein in host defence mechanisms of the kidney and genitourinary tract.


  • Atherosklerose und Urämie: Die Bedeutung nicht-traditioneller Risikofaktoren

    by Walter H. Hörl

    Arteriosclerosis, atherosclerosis and vascular calcification are causally related to the high morbidity and mortality of patients with chronic renal failure. Oxidative stress and carbonyl stress of uremia, dialysis procedure and/or intravenous iron therapy result in AGE (advanced glycation end-product), ALE (advanced lipoxidation end-product) and AOPP (advanced oxidation protein product) formation, favouring together with elevated CRP (C-reactive protein) levels the development of cardiovascular and cerebrovascular complications. Enhanced plasma levels of homocysteine and ADMA (asymmetric dimethylarginine) contribute to this process. In addition, in chronic renal insufficiency hyperphosphatemia and an enhanced calcium-x phosphorus ion product are associated with the morbidity and mortality of the patients, particularly in the presence of fetuin deficiency. Phosphorus, AGEs and AOPPs, beside other factors, catalyze the conversion of vascular smooth muscle cells to osteoblast-like cells (particularly in the presence of monocytes/macrophages), resulting in bone matrix protein formation. Other risk factors, such as age, male sex, smoking, hypertension, diabetes, chronic inflammation, insulin resistance or dyslipidemia (enhanced non-HDL-cholesterol) also contribute to the atherosclerotic risk profile of the patient with chronic renal insufficiency. While there is growing understanding of the mechanisms involved in arteriosclerosis, atherosclerosis and vascular calcification in uremia, we are still missing effective therapeutic maneuvers for reduction of excess mortality in uremic patients. Arteriosklerose, Atherosklerose und Gefäßverkalkungen sind ursächlich verantwortlich für die hohe Morbidität und Mortalität von Patienten mit chronischer Niereninsuffizienz. Oxidativer Stress und Carbonylstress durch die Urämie, die Dialysebehandlung und/oder die intravenöse Eisentherapie resultieren in der Bildung von AGEs (Advanced Glycation End-products), ALEs (Advanced Lipoxidation End-products) und AOPPs (Advanced Oxidation Protein Products). Dadurch und durch erhöhte CRP (C-reaktives Protein)-Spiegel werden kardiovaskuläre und zerebrovaskuläre Komplikationen begünstigt. Erhöhte Plasmaspiegel an Homozystein und ADMA (asymmetrisches Dimethylarginin) sind ebenfalls an diesem Prozess beteiligt. Auch die Hyperphosphatämie und ein erhöhtes Kalzium x Phosphat-lonenprodukt sind bei chronischer Niereninsuffizienz mit der Morbidität und Mortalität der Patienten assoziiert, vor allem bei Fetuinmangel. Phosphor, AGEs und AOPPs katalysieren neben anderen Faktoren die Umwandlung von glatten Gefäßmuskelzellen in “oste oblast-like cells”, vor allem in Gegenwart von Monozyten/Makrophagen, mit konsekutiver Bildung von Knochenmatrixproteinen. Andere Risikofaktoren wie Alter, männliches Geschlecht, Rauchen, Hypertonie, Diabetes, chronische Inflammation, Insulinresistenz oder Dyslipidämie (hohe Nicht-HDL-Cholesterinfraktion) komplettieren das atherogene Risikoprofil des Patienten mit chronischer Niereninsuffizienz. Während inzwischen die Mechanismen der Arteriosklerose, Atherosklerose und Gefäßverkalkung bei Urämie relativ gut untersucht sind, fehlen — zumindest teilweise — noch effektive Therapiemaßnahmen zur Reduktion der Exzessmortalität dieser Patienten.


  • Predialysis survey on anemia management: Patient referral

    by Walter H. Hörl, Iain C. Macdougall, Jérôme Rossert, Boleslaw Rutkowski, Jean-Pierre Wauters, Fernando Valderrábano


  • Open Access

    Non-erythropoietin-based anaemia management in chronic kidney disease

    by Walter H. HÖRl

    Renal anaemia starts earlier in the progression of chronic kidney disease (CKD) than was previously thought and is often inadequately monitored and treated. Current treatment guidelines recommend giving recombinant erythropoietin (rHuEPO) as soon as haemoglobin (Hb) concentration falls below 11 g/dl and alternative causes of anaemia have been ruled out. Recent studies show that, in practice, few patients receive rHuEPO in the pre‐dialysis period and Hb concentrations are often <9 g/dl at the start of haemodialysis. This is at odds with best practice since renal anaemia is a major risk factor for left ventricular hypertrophy. Many factors other than provision of rHuEPO therapy can affect the occurrence and severity of renal anaemia. Iron deficiency is the most common cause of resistance to rHuEPO and appropriate use of iron supplementation in patients with CKD is still being debated. The acute‐phase immune response has a more significant role in renal anaemia and rHuEPO resistance than previously believed, as demonstrated by the need for higher rHuEPO doses in patients with raised levels of C‐reactive protein. Women often need higher doses of rHuEPO than men, which may be related to differences in androgen levels between the sexes. Low erythropoietin concentrations are a major factor in diabetic nephropathy. Correction of anaemia with rHuEPO may slow progression of CKD by reducing oxidative stress. These and other factors need to be considered for the optimal treatment of patients with anaemia of CKD.


  • Open Access

    High dose intravenous iron: a note of caution

    by Josef Kletzmayr, Gere Sunder‐Plassmann, Walter H. Hörl

    The majority of patients with chronic kidney disease are anaemic. Iron deficiency should be corrected before treatment with recombinant human erythropoietin (rhuEpo) or novel erythropoiesis stimulating protein (NESP) is initiated. During maintenance rhuEpo or NESP therapy, iron supplementation is needed to prevent hyporesponsiveness to these drugs. On the other hand, iron supplementation is not without side‐effects, particularly if high dose intravenous (i.v.) iron is administered.


  • Open Access

    Adjunctive therapy in anaemia management

    by Walter H. HÖRl

    Iron supplementation is essential for adequate response to recombinant human erythropoietin (rHuEPO) or darbepoetin alfa. Oral iron therapy is often ineffective as the quantity of iron absorbed after oral intake may be insufficient to keep pace with the demands of rHuEPO‐stimulated erythropoiesis in patients with end‐stage renal disease (ESRD). Currently available i.v. iron preparations include dextran, iron gluconate, and iron sucrose. As rare, but serious, adverse reactions to i.v. iron dextran have been reported, alternative preparations may be preferred. Careful monitoring of iron parameters is required to avoid the effects of over‐treatment. Renal anaemia and iron therapy are associated with oxidative stress, leading to a shortening of the lifespan of red blood cells (RBC) and resistance to rHuEPO. rHuEPO therapy may also enhance oxidative stress on RBC. Oxidative stress can be attenuated or prevented by supplementation with vitamin E or melatonin. Vitamin E therapy has also been shown to have a rHuEPO‐sparing effect. Disturbances of carnitine metabolism may contribute to the development of renal anaemia in ESRD patients. Oral or i.v. l‐carnitine therapy results in an increase in haematocrit and a significant decrease in rHuEPO requirement in HD patients. As yet, there is no general recommendation for l‐carnitine supplementation for ESRD patients with renal anaemia.


    • 1 January 2002
      • p. S62-71

    Hemodialysis membranes: interleukins, biocompatibility, and middle molecules.

    by Walter H Hörl

    Maintenance hemodialysis patients display evidence of elevated interleukin-1 (IL-1) and tumor necrosis factor alpha release after stimulation either by contaminated dialysate, bioincompatible membrane material, or both. This release is followed by the stimulated secretion of a large number of other interleukins, particularly IL-6, the cytokine principally responsible for acute-phase protein synthesis. It has been shown that high levels of the circulating proinflammatory cytokines IL-1, tumor necrosis factor alpha, IL-6, and IL-13 are associated with mortality in hemodialysis patients. Essential functions of polymorphonuclear leukocytes--that is, phagocytosis, oxygen species production, upregulation of specific cell surface receptor proteins, or apoptosis--are disturbed in patients with end-stage renal disease. These are further altered as a result of complement activation by the hemodialysis procedure, particularly if bioincompatible dialyzers are used. Polymorphonuclear leukocyte degranulation occurring during extracorporeal circulation does not depend on complement activation but rather on intracellular calcium and the presence or absence of the degranulation inhibitory proteins angiogenin and complement factor D. Clinical signs and symptoms of end-stage renal disease patients are at least in part related to the accumulation of middle molecules such as beta(2)-microglobulin, parathyroid hormone, advanced glycation end products, advanced lipoxidation end products, advanced oxidation protein products (formed as a result of oxidative stress, carbonyl stress, or both), granulocyte inhibitory proteins, or leptin. Currently available membrane materials do not provide long-lasting, effective reduction of middle molecules in patients who require maintenance hemodialysis.